Luis Velazquez‐Vega

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Rac Inhibition As A Novel Therapeutic Strategy for EGFR/HER2 Targeted Therapy Resistant Breast Cancer”.

Rac Inhibition As A Novel Therapeutic Strategy for EGFR/HER2 Targeted Therapy Resistant Breast Cancer

Research Square(2020)10.21203/rs.3.rs-86620/v1

N/A

0DataRank · unranked

0 citations

María del Mar Maldonado, Julia Medina‐Velázquez, Angel Luis Troche‐Torres, Luis Velazquez‐Vega, Nilmary Grafals‐Ruiz +2 more

Overcoming Therapy Resistance in HER2‐positive Breast Cancer with the Dual Rac/Cdc42 Inhibitor MBQ‐167

The FASEB Journal(2021)10.1096/fasebj.2021.35.s1.03931

N/A

0DataRank · unranked

0 citations

Michael J. Rivera-Robles, Paula Rocío Vigo‐Morales, Suranganie Dharmawardhane, Luis Velazquez‐Vega

Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer

Translational Oncology(2024)10.1016/j.tranon.2024.101928

N/A

0DataRank · unranked

5 citations

Michael J. Rivera-Robles, Annelis O. Sánchez-Álvarez, Pablo E. Vivas‐Mejía, Miciely Aponte-Reyes, Ailed Cruz‐Collazo +6 more